Publications by authors named "Pamela Levine"
Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), variably express CD30. This phase 2, open-label study evaluated the efficacy of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in relapsed/refractory CD30(+) NHL. This planned subset analysis of B-cell NHLs includes 49 patients with DLBCL and 19 with other B-cell NHLs.
View Article and Find Full Text PDFArticle Synopsis
- Brentuximab vedotin, an antibody-drug conjugate targeting CD30, was studied for retreatment in patients with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL) who had relapsed after initial treatment.
- The study included 29 patients (21 with HL, 8 with ALCL) receiving brentuximab vedotin intravenously every three weeks, focusing on the safety and effectiveness of this retreatment approach.
- Results showed a 60% response rate in HL patients and an 88% rate in ALCL patients, with notable durations of response, while side effects were similar to those seen in earlier studies, apart from increased peripheral neuropathy.
Background: Epidemiologic studies of skin and soft tissue infections (SSTIs) depend upon accurate case identification. Our objective was to evaluate the positive predictive value (PPV) of electronic medical record data for identification of SSTIs in a primary care setting.
Methods: A validation study was conducted among primary care outpatients in an academic healthcare system.